Kalaris Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Kalaris Therapeutics, Inc. (KLRS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-58.77-190.42-168.71-171.96-69.78
Depreciation & Amortization0.000.40-0.351.390.58
Stock Based Compensation0.000.150.270.000.00
Change in Working Capital-25.31-1.09-15.2718.35-1.33
Change in Accounts Receivable0.210.000.000.000.00
Change in Accounts Payable-28.86-0.401.830.000.00
Change in Other Working Capital3.351.822.580.000.00
Other Operating Activities16.371.8242.2845.919.73
Net Cash from Operating Activities-67.71-14.13-142.05-106.32-60.81
Investing Activities
Capital Expenditures0.000.000.000.030.24
Sales/Maturities of Investments95.00-125.83-80.48186.01-169.26
Net Cash from Investing Activities95.0037.99-80.48185.98-169.50
Financing Activities
Common Stock Issued0.020.00126.960.00295.45
Other Financing Activities0.001.500.000.00-3.47
Net Cash from Financing Activities0.0214.24126.960.23291.98
Summary
Effect of Forex Changes on Cash0.850.000.00-0.04-0.09
Net Change in Cash28.170.11-95.5779.9061.67
Cash at Beginning of Period90.123.06202.51122.6661.08
Cash at End of Period118.293.17106.94202.51122.66
Free Cash Flow-67.71-14.13-142.05-106.35-61.05
Supplemental Disclosures
Income Taxes Paid0.000.000.610.000.00